头甲状腺癌:为什么地方区域控制"总是"重要?
L Lorini1, R Gili2, V Salvestrini3
1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
Oral oncology
|March 29, 2024
概括
将放射治疗与免疫检查点抑制剂相结合,为新的转移性头支状细胞癌 (HNSCC) 提供了一个有希望的方法. 这一战略旨在改善这种具有挑战性的诊断患者的生存结果.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 头部和部状细胞癌 (HNSCC) 占复发/转移病例的10%.
- 放射治疗 (RT) 已为局部发达的HNSCC建立,但在复发性/转移性情况下是有限的.
- 免疫检查点抑制剂 (ICI) 改善了复发性/转移性HNSCC的生存率,但总生存率的中位数仍然受到限制.
研究的目的:
- 探索将地方区域RT与ICI结合用于新的转移性HNSCC的潜力.
- 确定整合地方区域和系统治疗的关键决策因素.
- 改善同步新发转移性HNSCC患者的治疗结果.
主要方法:
- 关于治疗整合的文献综述和专家观点.
- 对转移性HNSCC的当前治疗模式的分析.
- 讨论RT和ICI的协同潜力.
主要成果:
- 地方区域RT和ICI的整合是一个有前途的治疗途径.
- 组合疗法可以提高新发转移的HNSCC的存活率和治疗疗效.
- 战略决策对于优化综合治疗方法至关重要.
结论:
- 将局域性放射治疗与免疫检查点抑制剂相结合,是治疗新发转移的头甲状腺癌的一个有希望的策略.
- 这种综合方法有可能改善整体生存率和治疗结果.
- 仔细考虑治疗顺序和患者选择对于成功实施至关重要.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...